Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function



Rating:

Share or cite this content

Citations should be made in the following way:
M. Elashmawy (Cambridge (Cambridgeshire), United Kingdom), J. Baker (Cambridge (Cambridgeshire), United Kingdom), T. Polychronakis (Cambridge (Cambridgeshire), United Kingdom). Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough.. 3150

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13) Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Effectiveness of 23-valent pneumococcal polysaccharide vaccine in preventing lower respiratory tract infections complicating chronic respiratory failure Source: Eur Respir J 2006; 28: Suppl. 50, 576s Year: 2006 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine Source: Eur Respir J 2002; 20: 813-818 Year: 2002 Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Should pneumococcal vaccines be used to prevent LRTI? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Eur Respir Rev 2008; 17: 43-45 Year: 2008 Perception and uptake of the influenza and pneumococcal vaccinations in patients with COPD Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Efficacy of influenza and pneumococcal vaccinations among patients with COPD Source: Annual Congress 2007 - Treatment of COPD Year: 2007